Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: John Curtis who wrote (759)	5/16/1999 9:22:00 AM
From: StockMiser	Read Replies (1) \| Respond to of 2344

Agreed 100%...with two caveats... 1 - If we get additional broker coverage along with valuation analysis showing that BIOM will, in fact, be worth $50/share once Theratope hits the market. This is one reason IMCL has actually sustained, and actually broke through, it's news related price spike. 2 - If Biomira gets the focus of a major media player, such as NY Times or WSJ. No doubt that BIOM couldn't sustain a price spike to $20....but such an article could do to BIOM's trading range what similar articles have done for ENMD and IMCL. Although we would come down from any initial spike, we could still end up in a trading range between $8-10 for a long time to come. Big media exposure often leads to more frequent media exposure - consider how every minor news item for ENMD hits CNBC - even though it's a tiny, pre-clinical stage biotech. Given the right circumstances, BIOM might very well continue to trade in it's present range, or significantly higher, even after the news "pop". SM